Clinical trials: Renal Carcinoma
Renal Cell Carcinoma, Urothelial Carcinoma
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent
- Trial name
- NCT03827837
- Testing
- SHR-1210, Famitinib
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Renal Cancer, Surgery-Complications
Assessment of Complications in Patients Who Underwent LPN According to the CCI
This study aims to compare the strength of the classical Clavien-Dindo classification system (CDC), which is a Likert scale analysis versus the comprehensive complication index (CCI), a new quantitative evaluation system, in…
- Trial name
- NCT05823545
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people
- Sponsor
- Samsun Liv Hospital
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Kidney Neoplasms
Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection).
- Trial name
- NCT05184504
- Testing
- Observational study
- Where
- 16 sites in Brazil
- Volunteers
- 211 people
- Sponsor
- Latin American Cooperative Oncology Group
Renal Cell Carcinoma, Hepatocellular Carcinoma
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
This project will develop and pilot test social support intervention for an underserved population, Hispanics in Arizona, who have high rates of kidney and liver cancer to improve health equity.
- Trial name
- NCT05418387
- Testing
- Social Support Network Intervention, Control (Patient Navigation Service)
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Arizona
Kidney Cancer
PS-341 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of PS-341 is more effective in treating metastatic kidney cancer.
- Trial name
- NCT00025376
- Testing
- PS-341, Tumor Biopsy
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Chicago
Solid Tumor, Solid Carcinoma
Imaging of Solid Tumors Using 18F-TRX
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan.
- Conditions
- Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- NCT06942104
- Testing
- 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Rahul Aggarwal
Renal Cancer
Kidney Cancer DNA Registry
This registry will help us develop better methods of: Preventing these cancers Diagnosing these cancers Treating these cancers
- Trial name
- NCT02087852
- Testing
- salvia for germline DNA, the Kidney Cancer Questionnaire, Family History Questionnaire (when applicable)
- Where
- 7 sites in United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma Recurrent
Study of the Combination of CM082 With Everolimus in Patients With mRCC
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese Patients With Advanced Renal Cell Carcinoma.
- Trial name
- NCT02577458
- Testing
- CM082, Everolimus
- Where
- China
- Volunteers
- 18 people
- Sponsor
- AnewPharma
Carcinoma, Renal Cell
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
All patients who participate in this study will receive pazopanib. Pazopanib is an oral drug (pill) that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer.
- Trial name
- NCT01221506
- Testing
- Pazopanib, DCE-MRI and Quantitative Doppler Ultrasound
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
This phase Ib trial studies the side effects and best dose of DS3201 when given together with and ipilimumab for the treatment of patients with prostate, urothelial, or renal cell cancer that has spread to other places in the…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04388852
- Testing
- Ipilimumab, Valemetostat
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer, Metastatic Cancer
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00814021
- Testing
- sunitinib malate
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Institut Claudius Regaud
Non-Clear Cell Renal Cell Carcinoma
Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma
This study is testing a new treatment approach for people who have had surgery to remove a type of kidney cancer called non-clear cell renal cell carcinoma (non-ccRCC).
- Trial name
- NCT07488533
- Testing
- Serplulimab in combination with Fruquintinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured patients (age >= 18 years and < 65 years).
- Trial name
- NCT01381614
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Adult Polycystic Kidney Disease, Kidney Neoplasms
Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function
The number of people with kidney disease is constantly rising and renal failure represents one of the major health care burdens globally.
- Conditions
- Adult Polycystic Kidney Disease, Kidney Neoplasms, Kidney Dysfunction
- Trial name
- NCT03442647
- Testing
- sinistrin clearance dynamic measurement
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Thomas Mueller
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057889
- Testing
- ipilimumab
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Kidney Tumor, Renal Cancer
Decision Aid (DA) for Renal Patients
The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses.
- Trial name
- NCT05387863
- Testing
- Decision Aid (DA) Web Tool, Institutional Pamphlet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- NYU Langone Health
Kidney Cancer
Bryostatin 1 in Treating Patients With Metastatic Kidney Cancer
Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have metastatic kidney cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003968
- Testing
- bryostatin 1
- Where
- 17 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC).
- Trial name
- NCT00334282
- Testing
- Pazopanib
- Where
- 99 sites in Argentina, Australia and 23 more
- Volunteers
- 435 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.